Video

Molecular Testing in Colorectal Cancer

For High-Definition, Click

Testing for microsatellite instability (MSI) has gained acceptance in guidelines as part of the standard workup for patients with colorectal cancer (CRC). Reflexive MSI testing for patients with CRC varies among institutions. While the age to begin testing can very, it remains essential that patients with familial syndromes are followed closely. It is important to work with the pathology department, in order to fully utilize the testing method that has been operationalized and standardized, explains Herbert Hurwitz, MD.

It is a major challenge for primary care physicians to stay up to date on survivorship recommendations for every disease and the concern is that a lot of these patients may be lost to follow up. Patients with familial MSI-high CRC require follow up for the rest of their lives and are at risk for other cancers as well, notes Axel Grothey, MD.

MSI-high results can be utilized to guide treatment decisions regarding adjuvant therapy in stage II disease. Whether to give adjuvant chemotherapy in a patient with intermediate-risk stage II CRC is a complex decision that can be aided with the use of MSI testing.

Related Videos
Eunice S. Wang, MD
Marcella Ali Kaddoura, MD
Mary B. Beasley, MD, discusses molecular testing challenges in non–small cell lung cancer and pancreatic cancer.
Mary B. Beasley, MD, discusses the multidisciplinary management of NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Mary B. Beasley, MD, discusses the role of pathologists in molecular testing in non–small cell lung cancer and pancreatic cancer.
Mary B. Beasley, MD, discusses the role of RNA and other testing considerations for detecting NRG1 and other fusions in solid tumors.
Mary B. Beasley, MD, discusses the prevalence of NRG1 fusions in non–small cell lung cancer and pancreatic cancer.
Yelena Y. Janjigian, MD, chief, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center
Cedric Pobel, MD
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine